Transforming Growth Factor beta2
"Transforming Growth Factor beta2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A TGF-beta subtype that was originally identified as a GLIOBLASTOMA-derived factor which inhibits the antigen-dependent growth of both helper and CYTOTOXIC T LYMPHOCYTES. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta2 and TGF-beta2 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor.
| Descriptor ID |
D053781
|
| MeSH Number(s) |
D12.644.276.374.687.200 D12.644.276.954.775.200 D12.776.467.374.687.200 D12.776.467.942.775.200 D23.529.374.687.200 D23.529.942.775.200
|
| Concept/Terms |
Transforming Growth Factor beta2- Transforming Growth Factor beta2
- Glioblastoma-Derived T-Cell Suppressor Factor
- Glioblastoma Derived T Cell Suppressor Factor
- Cartilage-Inducing Factor-B
- Cartilage Inducing Factor B
- Polyergin
- TGF-beta2
- TGF-beta-2
- BSC-1 Cell Growth Inhibitor
- BSC 1 Cell Growth Inhibitor
- Suppressor Factor, T-Cell, Glioblastoma-Derived
|
Below are MeSH descriptors whose meaning is more general than "Transforming Growth Factor beta2".
Below are MeSH descriptors whose meaning is more specific than "Transforming Growth Factor beta2".
This graph shows the total number of publications written about "Transforming Growth Factor beta2" by people in this website by year, and whether "Transforming Growth Factor beta2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Transforming Growth Factor beta2" by people in Profiles.
-
Fry D, Groepper D, MacCarrick G, Demo EM, Thomas MJ, Wilkes MJ, Lyons MJ, Tucker ME, Steding C, Fleischer J. Loeys-Dietz syndrome caused by 1q41 deletion including TGFB2 is associated with a neurodevelopmental phenotype. Am J Med Genet A. 2022 07; 188(7):2237-2241.
-
VanOudenhove JJ, Medina R, Ghule PN, Lian JB, Stein JL, Zaidi SK, Stein GS. Transient RUNX1 Expression during Early Mesendodermal Differentiation of?hESCs Promotes Epithelial to Mesenchymal Transition through TGFB2 Signaling. Stem Cell Reports. 2016 11 08; 7(5):884-896.
-
Becker MA, Ibrahim YH, Oh AS, Fagan DH, Byron SA, Sarver AL, Lee AV, Shaw LM, Fan C, Perou CM, Yee D. Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. PLoS One. 2016; 11(3):e0150564.
-
Brown JP, Galassi TV, Stoppato M, Schiele NR, Kuo CK. Comparative analysis of mesenchymal stem cell and embryonic tendon progenitor cell response to embryonic tendon biochemical and mechanical factors. Stem Cell Res Ther. 2015 May 09; 6:89.
-
Liu H, Zhang C, Zhu S, Lu P, Zhu T, Gong X, Zhang Z, Hu J, Yin Z, Heng BC, Chen X, Ouyang HW. Mohawk promotes the tenogenesis of mesenchymal stem cells through activation of the TGF? signaling pathway. Stem Cells. 2015 Feb; 33(2):443-55.
-
Yang HP, Schneider SS, Chisholm CM, Browne EP, Mahmood S, Gierach GL, Lenington S, Anderton DL, Sherman ME, Arcaro KF. Association of TGF-?2 levels in breast milk with severity of breast biopsy diagnosis. Cancer Causes Control. 2015 Mar; 26(3):345-54.
-
Otero JE, Stevens JW, Malandra AE, Fredericks DC, Odgren PR, Buckwalter JA, Morcuende J. Osteoclast inhibition impairs chondrosarcoma growth and bone destruction. J Orthop Res. 2014 Dec; 32(12):1562-71.
-
Arcaro KF, Browne EP, Qin W, Zhang K, Anderton DL, Sauter ER. Differential expression of cancer-related proteins in paired breast milk samples from women with breast cancer. J Hum Lact. 2012 Nov; 28(4):543-6.